NCT05195827撤回3 期
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults With Hypertension
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Change in 24 hour Systolic Blood Pressure
研究概览
简要总结
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension
详细描述
Approximately 60 subjects with primary hypertension are treated for 8 weeks with PRM125 to determine if Ambulatory Blood Pressure is changed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •primary hypertension
排除标准
- •medical conditions that preclude evaluation and/or adversely effect subject safety
研究组 & 干预措施
PRM125
Experimental
PRM125
干预措施: PRM-125 (Drug)
结局指标
主要结局
Change in 24 hour Systolic Blood Pressure
时间窗: 8 weeks
次要结局
- Change in 24 hour Diastolic Blood Pressure(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT01358227Proacta, Incorporated26
已完成
2 期
Feasibility And Safety Study Of rhBMP-2/CPM For Hip FracturesFracturesNCT00384358Wyeth is now a wholly owned subsidiary of Pfizer108
已完成
2 期
Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMDOsteoporosisNCT00752557Pfizer50
已完成
1 期
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced CancerAdvanced CancerNCT01423903Otsuka Pharmaceutical Development & Commercialization, Inc.45
已完成
1 期
Extension Study of PRX-102 for up to 60 MonthsFabry DiseaseNCT01981720Protalix15